VYNE - VYNE Therapeutics Inc
0.6018
0.012 1.928%
Share volume: 114,333
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$0.59
0.01
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
| Report Date | 05-09-2024 | 08-14-2024 | 11-07-2024 | 03-06-2025 | 05-08-2025 | 08-14-2025 | |
| Total revenue | 98.000 K | 198.000 K | 121.000 K | 84.000 K | 202.000 K | 69.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 98.000 K | 198.000 K | 121.000 K | 84.000 K | 202.000 K | 69.000 K | |
| 102.04% | -38.89% | -30.58% | 140.48% | -65.84% | |||
| Operating expenses | 7.478 M | 10.594 M | 13.212 M | 12.854 M | 9.399 M | 7.611 M | |
| Selling general and admin | 3.770 M | 3.288 M | 2.964 M | 3.170 M | 3.275 M | 2.730 M | |
| Research and development | 3.708 M | 7.306 M | 10.248 M | 9.684 M | 6.124 M | 4.881 M | |
| Total expenses | 7.478 M | 10.594 M | 13.212 M | 12.854 M | 9.399 M | 7.611 M | |
| 41.67% | 24.71% | -2.71% | -26.88% | -19.02% | |||
| Operating income | -7.380 M | -10.396 M | -13.091 M | -12.770 M | -9.197 M | -7.542 M | |
| Ebit | -7.380 M | -9.395 M | -12.157 M | -12.010 M | -8.603 M | -5.747 M | |
| Pretax income | -6.241 M | -9.395 M | -12.157 M | -12.010 M | -8.603 M | -5.747 M | |
| 50.54% | 29.40% | -1.21% | -28.37% | -33.20% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 4.000 K | 0.000 | 0.000 | |
| Net income basic | -6.249 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | |||||||
| Net income | -6.249 M | -9.406 M | -12.157 M | -12.022 M | -8.611 M | -5.755 M | |
| -50.52% | -29.25% | 1.11% | 28.37% | 33.17% |